AVE-0118

Details

Stereochemistry	ACHIRAL
Molecular Formula	C30H29N3O3
Molecular Weight	479.5696
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C(CC(=O)NCC2=CC=CC=C2C3=CC=CC=C3C(=O)NCCC4=CC=CN=C4)C=C1

InChI

InChIKey=CHDSRMIDIQABTP-UHFFFAOYSA-N

InChI=1S/C30H29N3O3/c1-36-25-14-12-22(13-15-25)19-29(34)33-21-24-8-2-3-9-26(24)27-10-4-5-11-28(27)30(35)32-18-16-23-7-6-17-31-20-23/h2-15,17,20H,16,18-19,21H2,1H3,(H,32,35)(H,33,34)

HIDE SMILES / InChI

Molecular Formula	C30H29N3O3
Molecular Weight	479.5696
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16835355 | http://en.sanofi.com/Images/16151_AR_2005_EN.pdf

AVE-0118 is a Kv1.5 blocker which was developed by Aventis Pharma for the treatment of cardiovascular diseases. The drug reached phase II of clinical trilas in patients with atrial fibrillation, however its development was terminated.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Voltage-gated potassium channel subunit Kv1.5 43 Target ID: CHEMBL4306 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16835355	Blocker 555		5.6 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Atrial fibrillation 131 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17157284	Primary		Phase II 1147	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
Axon MedChem	2243	https://www.axonmedchem.com/product/2243
eMolecules	49435328	https://orderbb.emolecules.com/search/#?query=49435328
Molnova	M14669	https://www.molnova.com/en/serch-list.html?keywords=M14669
MolPort	MolPort-042-665-842	https://www.molport.com/shop/molecule-link/MolPort-042-665-842
MuseChem	I003302	https://www.musechem.com/product/I003302.html
Ryan Scientific	101-94199	https://ryansci.com/products?q=101-94199&list_q=&search_type=exact

PubMed

Title	Date	PubMed
Blockade of atrial-specific K+-currents increases atrial but not ventricular contractility by enhancing reverse mode Na+/Ca2+-exchange.	2007-01-01	17157284
Properties of a time-dependent potassium current in pig atrium: evidence for a role of kv1.5 in repolarization.	2006-11	16916995
Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation.	2006-10	16835355

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

The acutely dilated rabbit atria was treated with 0.3-10 microM AVE-0118. AVE-0118 concentration-dependently increased the atrial effective refractory period reduced the atrial fibrillation inducibility.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 20:30:28 GMT 2025` Edited by `admin` on `Mon Mar 31 20:30:28 GMT 2025`
Record UNII	Q1B712V03A
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

(1,1'-BIPHENYL)-2-CARBOXAMIDE, 2'-((((4-METHOXYPHENYL)ACETYL)AMINO)METHYL)-N-(2-(3-PYRIDINYL)ETHYL)-

Preferred Name

English

AVE-0118

Common Name

English

2'-((2-(4-METHOXYPHENYL)ACETYLAMINO)METHYL)BIPHENYL-2-CARBOXYLIC ACID (2-PYRIDIN-3-YL-ETHYL)AMIDE

Systematic Name

English

(1,1'-BIPHENYL)-2-CARBOXAMIDE, 2'-(((2-(4-METHOXYPHENYL)ACETYL)AMINO)METHYL)-N-(2-(3-PYRIDINYL)ETHYL)-

Systematic Name

English

Code System Code Type Description

CAS

498577-53-0